Madrigal Pharmaceuticals (MDGL) Price Target Raised to $125.00
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target increased by JMP Securities from $63.00 to $125.00 in a research report sent to investors on Wednesday, The Fly reports. JMP Securities currently has an outperform rating on the biopharmaceutical company’s stock.
A number of other research firms have also recently issued reports on MDGL. Roth Capital initiated coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, October 19th. They issued a buy rating and a $62.00 price target for the company. HC Wainwright raised their price target on shares of Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a buy rating in a report on Wednesday. Finally, Evercore ISI initiated coverage on shares of Madrigal Pharmaceuticals in a report on Friday, September 22nd. They issued an outperform rating and a $65.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $113.00.
Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) traded down $0.80 on Wednesday, reaching $81.57. 276,635 shares of the company’s stock traded hands, compared to its average volume of 253,837. Madrigal Pharmaceuticals has a 52 week low of $13.09 and a 52 week high of $101.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.11. equities research analysts anticipate that Madrigal Pharmaceuticals will post -2.57 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of MDGL. VHCP Management II LLC purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter worth $1,349,000. Shikiar Asset Management Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 52.8% during the third quarter. Shikiar Asset Management Inc. now owns 23,141 shares of the biopharmaceutical company’s stock worth $1,041,000 after purchasing an additional 8,000 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter worth $2,274,000. Citigroup Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the second quarter worth $185,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Madrigal Pharmaceuticals during the second quarter worth $109,000. 21.40% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/12/09/madrigal-pharmaceuticals-mdgl-price-target-raised-to-125-00.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.